Roquefort Therapeutics plc

Equities

ROQ

GB00BMDQ2T15

Investment Management & Fund Operators

Market Closed - London S.E. Other stock markets 16:35:14 07/06/2024 BST			5-day change	1st Jan Change
4.9 ^GBX	0.00%		-2.00%	-32.41%

05-23	Windward wins deal; Kodal progresses at Bougouni	AN
05-23	Roquefort Therapeutics plc Announces Executive and Board Changes	CI

Roquefort Therapeutics says new mRNA platform "fits very well"

March 09, 2023 at 08:03 am

(via NewsDirect)

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Proactive's Thomas Warner after announcing the biotech company has developed a new platform of potential anti-cancer messenger RNA (mRNA) therapeutics.

Reginald reveals the reasons for the move, saying that "developing cutting edge medicines using innovative new approaches" is "what Roquefort is all about."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Roquefort Therapeutics plc

Windward wins deal; Kodal progresses at Bougouni	05-23	AN
Roquefort Therapeutics plc Announces Executive and Board Changes	05-23	CI
EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany	04-26	AN
Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35	04-26	MT
Roquefort Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Roquefort cancels fundraise after "unusual" stock movements	04-05	AN
Roquefort Therapeutics Shelves Potential Placing Following Unusual Price Movements	04-05	MT
Roquefort celebrates "significant milestones" in cancer research	03-11	AN
Roquefort Therapeutics plc Provides an Update on the Development of the Midkine Midkine mRNA and STAT-6 siRNA programs	03-11	CI
Roquefort hails further MK studies, licence talks continue	02-06	AN
Roquefort Therapeutics plc Provides an Update on Its Pre-Clinical Drug Development Programs	02-06	CI
Roquefort Therapeutics Announces Significant Mesodermal Killer Cell Milestone	11-06	CI
EARNINGS: Biome loss widens; Amicorp focused on growth post-IPO	27/09/23	AN
Roquefort Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023	27/09/23	CI
Roquefort files patent application for mRNA and RNA therapies	14/08/23	AN
Roquefort Therapeutics Files International Patent for Anti-cancer Therapeutics	14/08/23	MT
Roquefort Therapeutics plc Announces the Successful Filing of the International Phase PCT Patent for Its Proprietary Anti-Cancer mRNA and RNA Oligonucleotide Therapeutics	14/08/23	CI
Roquefort announces new sirNA sequences and patent filing	07/08/23	AN
Roquefort Therapeutics Completes Development of Four Novel Small Interfering RNA Sequences; Shares Up 5%	07/08/23	MT
Anpario trading in line, Likewise Group sales rise	29/06/23	AN
Plant Health Care announces GBP2.8 million fundraise	22/06/23	AN
Roquefort Therapeutics Expects Q4 Closing for In Vivo Studies for Anti-Cancer Program	22/06/23	MT
Roquefort Therapeutics celebrates cancer antibody trial results	19/06/23	AN
Roquefort Therapeutics' Bone Cancer Antibodies Lower Tumor Growth Rate in Efficacy Trial	19/06/23	MT
Roquefort says anti-cancer mRNA study shows positive results	13/06/23	AN

Chart Roquefort Therapeutics plc

Duration

Period

More charts

Company Profile

Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.

Sector

Investment Management & Fund Operators

Calendar

27/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Investment Management & Fund Operators

	1st Jan change	Capi.
ROQUEFORT THERAPEUTICS PLC	-32.41%	8.05M
BLACKROCK, INC.	-5.31%	114B
UBS GROUP AG	+8.89%	102B
BROOKFIELD CORPORATION	+7.51%	64.37B
APOLLO GLOBAL MANAGEMENT, INC.	+20.57%	63.93B
BANK OF NEW YORK MELLON CORPORATION (THE)	+15.87%	45.1B
AMERIPRISE FINANCIAL, INC.	+12.32%	42.37B
3I GROUP PLC	+20.86%	35.9B
T. ROWE PRICE GROUP INC.	+7.30%	25.8B
STATE STREET CORPORATION	-3.49%	22.52B

Other Investment Management & Fund Operators